版本:
中国

BRIEF-Progenics Pharmaceuticals announces positive topline results from registrational Phase 2B trial of Azedra®

March 30 Progenics Pharmaceuticals Inc

* Progenics Pharmaceuticals announces positive topline results from registrational phase 2b trial of azedra®

* Progenics Pharmaceuticals Inc - study achieves primary endpoint

* Progenics Pharmaceuticals Inc - secondary endpoint shows favorable tumor response to therapy

* Progenics Pharmaceuticals Inc - company to submit nda in mid-2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐